Supreme Court docket asks Centre to border statutory guidelines for pharma advertising and marketing

The Supreme Court docket (SC) on Thursday directed the Centre to represent a committee to look at and advocate statutory laws governing pharmaceutical (pharma) corporations’ advertising and marketing practices, together with items and different advantages supplied to docs to advertise their merchandise.

 

A Bench of Justices Vikram Nath and Sandeep Mehta mentioned the committee would contemplate solutions and representations on the problem and make suggestions to the Union authorities. The matter shall be taken up on January 29, 2027, for consideration of the Centre’s compliance affidavit.

 

The order got here on a petition filed by the Federation of Medical and Gross sales Representatives’ Associations of India and others looking for a legally enforceable framework to control pharma corporations’ promotion of medicines amongst healthcare professionals.

  

The dispute centres on practices through which drug corporations present docs with items, hospitality, journey amenities, financial advantages or different incentives as a part of product promotion. The priority raised earlier than the court docket is that such advantages can affect docs’ prescribing choices, doubtlessly growing prescriptions of explicit medicines and including to sufferers’ healthcare prices.

 

The case additionally issues the Uniform Code for Pharmaceutical Advertising and marketing Practices (UCPMP), 2024, issued by the Division of Prescribed drugs to control interactions between drug corporations and healthcare professionals. The code prohibits pharma corporations and their brokers from offering private items, financial advantages, and hospitality to docs and their members of the family. It additionally restricts corporations from extending journey amenities to healthcare professionals for conferences and comparable occasions, topic to specified circumstances.

 

The SC had earlier questioned whether or not the UCPMP had satisfactory enforcement mechanisms and whether or not it must be given statutory backing.

 

Through the proceedings, Solicitor Basic Tushar Mehta, showing for the Centre, mentioned the Centre proposed a three-member committee to look at whether or not a statutory framework was vital and, in that case, what type it ought to take.

 

The Centre mentioned current laws offered for disciplinary motion towards docs accepting items, journey, hospitality or financial grants from pharma corporations.

 

The petitioners, nevertheless, argued that there was no comparable statutory mechanism to penalise corporations providing such inducements.

 

Senior advocate Sanjay Parikh, showing for the petitioners, additionally identified that the Centre had knowledgeable the court docket in 2022 {that a} high-level committee had already examined the necessity for a legally enforceable mechanism.

 

The petitioners relied on the SC’s 2022 judgment in M/s Apex Laboratories versus Deputy Commissioner of Earnings Tax.

 

In that case, the court docket held that pharma corporations couldn’t declare tax deductions for freebies offered to docs and famous that such advantages might affect prescriptions. The court docket had referred to examples together with gold cash, digital items, and funding of overseas journeys and medical conferences.